Target intelligence / Profile preview

Off-target mRNAs with partial complementarity to the shRNA guide strand (shRNA off-targets)

Target
shRNA off-targets
Molecular classification
Messenger RNA (mRNA), Nucleic acid
01

Overview

Off-target mRNAs with partial complementarity to the shRNA guide strand represent a significant challenge in RNA interference (RNAi) technology, where short hairpin RNAs (shRNAs) inadvertently silence genes other than the intended target. This phenomenon primarily occurs through a microRNA-like mechanism, where the 'seed region' (nucleotides 2-8) of the shRNA guide strand binds to the 3' untranslated region (UTR) of unintended transcripts (Jackson et al., 2003; Birmingham et al., 2006). Such interactions can lead to widespread changes in the cellular transcriptome, potentially causing false-positive results in functional genomics research or severe toxicity in clinical applications. In therapeutic contexts, high levels of shRNA expression can also saturate the endogenous RNAi machinery, such as Exportin-5 and the RNA-induced silencing complex (RISC), interfering with natural microRNA processing and leading to organ failure or death (Grimm et al., 2006). Strategies to mitigate these effects include optimized sequence design to avoid common seed sequences, chemical modifications of the guide strand, and the use of inducible or tissue-specific promoters to limit shRNA concentration (Sigoillot et al., 2012). Understanding and predicting these off-target interactions is critical for the development of safe and effective RNAi-based therapeutics.

Other names
Seed-based off-targetsmiRNA-like off-target effectsshRNA-mediated off-target silencingRNAi off-targetsUnintended mRNA targets
02

Mechanism of action

RNA interference (RNAi) pathway mediated by the RNA-induced silencing complex (RISC), where the guide strand binds to partially complementary sequences (typically in the 3' UTR) of unintended mRNAs, leading to translational repression or mRNA degradation.

03

Biological functions

Gene expression regulationRNA interference (RNAi)
04

Disease associations

ToxicityUnintended phenotypic changesHepatotoxicityNeurotoxicity
05

Safety considerations

HepatotoxicityNeurotoxicitySaturation of Exportin-5Saturation of RISCUnintended gene silencingLethality in animal models
06

Interacting drugs

Short hairpin RNA (shRNA)

1 more in the full profile.

07

Biomarkers

Transcriptome profiling (RNA-seq)Reporter assaysCell viability assaysAlanine aminotransferase (ALT) for liver toxicity

Beyond the preview

Go deeper on Off-target mRNAs with partial complementarity to the shRNA guide strand (shRNA off-targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Off-target mRNAs with partial complementarity to the shRNA guide strand (shRNA off-targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call